FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence

Bone

Volumn 47, Issue 1, 2010, Pages 102-110

  Krejci, Pavel ^a,b,c   Prochazkova, Jirina ^a   Smutny, Jiri ^a   Chlebova, Katarina ^a   Lin, Patricia ^c   Aklian, Anie ^c   Bryja, Vitezslav ^a,b   Kozubik, Alois ^a,b   Wilcox, William R ^c,d  

^a MASARYK UNIVERSITY   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cartilage; FGFR3; MAP kinase; Oncogene; Senescence; Skeletal dysplasia

Indexed keywords

ALPHA GLUCOSIDASE; CAVEOLIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; LAMIN A; MITOGEN ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSGELIN;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL AGING; CELL GROWTH; CELL SHAPE; CHONDROGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE ACTIVATION; GROWTH INHIBITION; NONHUMAN; ONCOGENE; PHENOTYPE; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL AGING; CELL PROLIFERATION; CELL SHAPE; CHONDROCYTES; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; ONCOGENES; PHENOTYPE; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 77954762934     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.03.021     Document Type: Article

References (47)

1. Passos-Bueno M.R., Wilcox W.R., Jabs E.W., Sertie A.L., Alonso L.G., Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 1999, 14:115-125.
2. Ornoy A., Adomian G.E., Eteson D.J., Burgeson R.E., Rimoin D.L. The role of mesenchyme-like tissue in the pathogenesis of thanatophoric dysplasia. Am J Med Genet 1985, 21:613-630.
3. Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K., McGowan S.J., et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 2009, 41:1247-1252.
4. Hafner C., Stoehr R., van Oers J.M., Zwarthoff E.C., Hofstaedter F., Landthaler M., et al. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. Br J Dermatol 2009, 160:546-551.
5. Hernández S., de Muga S., Agell L., Juanpere N., Esgueva R., Lorente J.A., et al. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol 2009, 22:848-856.
6. Plowright E.E., Li Z., Bergsagel P.L., Chesi M., Barber D.L., Branch D.R., et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000, 95:992-998.
7. Li Z., Zhu Y.X., Plowright E.E., Bergsagel P.L., Chesi M., Patterson B., et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood 2001, 97:2413-2419.
8. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
9. Yasoda A., Komatsu Y., Chusho H., Miyazawa T., Ozasa A., Miura M., et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004, 10:80-86.
10. Nowroozi N., Raffioni S., Wang T., Apostol B.L., Bradshaw R.A., Thompson L.M. Sustained Erk1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet 2005, 14:1529-1538.
11. Murakami S., Balmes G., McKinney S., Zhang Z., Givol D., de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 2004, 18:290-305.
12. Matsushita T., Wilcox W.R., Chan Y.Y., Kawanami A., Bukulmez H., Balmes G., et al. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet 2008, 18:227-240.
13. Krejci P., Bryja V., Pachernik J., Hampl A., Pogue R., Mekikian P., et al. FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res 2004, 297:152-164.
14. Yaswen P., Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007, 128:233-234.
15. Krejci P., Masri B., Fontaine V., Mekikian P.B., Weis M., Prats H., et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and cartilage matrix homeostasis. J Cell Sci 2005, 118:5089-5100.
16. Krejci P., Salazar L., Goodridge H.S., Kashiwada T.A., Schibler M.J., Jelinkova P., et al. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J Cell Sci 2008, 121:272-281.
17. Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A., Thompson L.M., et al. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS ONE 2008, 3:e3961.
18. Wilcox W.R., Tavormina P.L., Krakow D., Kitoh H., Lachman R.S., Wasmuth J.J., et al. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 1998, 78:274-281.
19. Dailey L., Laplantine E., Priore R., Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol 2003, 161:1053-1066.
20. Aikawa T., Sagre G.V., Lee K. Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2. J Biol Chem 2001, 276:29347-29352.
21. Itahana K., Campisi J., Dimri G.P. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007, 371:21-31.
22. Benvenuti S., Cramer R., Bruce J., Waterfield M.D., Jat P.S. Identification of novel candidates for replicative senescence by functional proteomics. Oncogene 2002, 21:4403-4413.
23. Benanti J.A., Williams D.K., Robinson K.L., Ozer H.L., Galloway D.A. Induction of extracellular matrix-remodeling genes by the senescence-assosiated protein Apa-1. Mol Cell Biol 2002, 22:7385-7397.
24. Park W.Y., Park J.S., Cho K.A., Kim D.I., Ko Y.G., Seo J.S., et al. Up-regulation of caveolin attenuates epidermal growth factor signaling in senescent cells. J Biol Chem 2000, 275:20847-20852.
25. Barradas M., Gonos E.S., Zebedee Z., Kolettas E., Petropoulou C., Delgado M.D., et al. Identification of a candidate tumor-suppressor gene specifically activated during ras-induced senescence. Exp Cell Res 2002, 273:127-137.
26. Gonos E.S., Derventzi A., Kveiborg M., Agiostratidou G., Kassem M., Clark B.F.C., et al. Cloning and identification of genes that associate with mammalian replicative senescence. Exp Cell Res 1998, 240:66-74.
27. Dimri G.P., Testori A., Acosta M., Campisi J. Replicative senescence, aging and growth-regulatory transcription factors. Biol Signals 1996, 5:154-162.
28. Zuckerman V., Wolyniec K., Sionov R.V., Haupt S., Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009, 19:3-15.
29. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000, 20:3224-3233.
30. Ljungman M., O'Hagan H.M., Paulsen M.T. Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 2001, 20:5964-5971.
31. Karpinich N.O., Tafani M., Rothman R.J., Russo M.A., Farber J.L. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002, 277:16547-16552.
32. Nakagawa H., Opitz O.G. Inducing cellular senescence using defined genetic elements. Methods Mol Biol 2007, 371:167-178.
33. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84:1415-1420.
34. Horton W.A., Hall J.G., Hecht J.T. Achondroplasia. Lancet 2007, 14:162-172.
35. Segev O., Chumakov I., Nevo Z., Givol D., Madar-Shapiro L., Sheinin Y., et al. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. Hum Mol Genet 2000, 9:249-258.
36. Chen L., Li C., Qiao W., Xu X., Deng C. A Ser(365)->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 2001, 10:457-465.
37. Li C., Chen L., Iwata T., Kitagawa M., Fu X.Y., Deng C.X. A lys644glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet 1999, 8:35-44.
38. Sahni M., Raz R., Coffin J.D., Levy D., Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 2001, 128:2119-2129.
39. Naski M.C., Colvin J.S., Coffin J.D., Ornitz D.M. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 1998, 125:4977-4988.
40. Legeai-Mallet L., Benoist-Lasselin C., Delezoide A.L., Munnich A., Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 1998, 273:13007-13014.
41. Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y., Tanaka H. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. Bone 2007, 41:273-281.
42. Iwata T., Li C.L., Deng C.X., Francomano C.A. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum Mol Genet 2001, 10:1255-1264.
43. Raucci A., Laplantine E., Mansukhani A., Basilico C. Activation of the Erk1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes. J Biol Chem 2004, 279:1747-1756.
44. Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 2006, 119:380-387.
45. Zhang R., Murakami S., Coustry F., Wang Y., de Crombrugghe B. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc Natl Acad Sci USA 2006, 103:365-370.
46. Laplantine E., Rossi F., Sahni M., Basilico C., Cobrinik D. FGF signaling targets the pRb-related p107 and p130 proteins to induce chondrocyte growth arrest. J Cell Biol 2002, 158:741-750.
47. Rozenblatt-Rosen O., Mosonego-Ornan E., Sadot E., Madar-Shapiro L., Sheinin Y., Ginsberg D., et al. Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations. J Cell Sci 2002, 115:553-562.